HR Execs on the Move

Tetracore

www.tetracore.com

 
At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tetracore.com
  • 9901, Belward Campus Drive
    Rockville, MD USA 20850
  • Phone: 240.268.5400

Executives

Name Title Contact Details
Aymeric de Vazeille
Director of R&D-Molecular Devices Profile

Similar Companies

Alfa Scientific Designs

Alfa Scientific Designs, Inc is a Poway, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cerecin

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin`s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of medium-chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world`s leading manufacturers of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.

Verano Holdings

Verano™ Holdings is a national, vertically-integrated operator of licensed cannabis cultivation, manufacturing and retail facilities dedicated to improving lives by providing safe access to effective organic cannabis products that enhance health and wellness and by positively impacting the communities it serves.

Tallac Therapeutics

Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).